➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTYVIO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ENTYVIO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00619489 Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 2 2007-12-01 This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases.
NCT00783692 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 3 2008-12-01 The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
NCT00783718 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis Completed Millennium Pharmaceuticals, Inc. Phase 3 2009-01-01 The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
NCT01177228 Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Completed Millennium Pharmaceuticals, Inc. Phase 2 2007-05-01 The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative colitis (UC).
NCT01224171 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 3 2010-11-01 This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
NCT01981616 Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Completed Millennium Pharmaceuticals, Inc. Phase 1 2011-09-01 The primary purpose of this study is to determine the rates of seroconversion to a hepatitis B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo. Secondary objectives are to determine the rates of seroconversion to an oral cholera vaccine series, assess change in anti-hepatitis B surface antibodies and assess the safety and tolerability of a single 750-mg IV dose of vedolizumab.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ENTYVIO

Condition Name

Condition Name for ENTYVIO
Intervention Trials
Ulcerative Colitis 11
Crohn's Disease 10
Crohn Disease 6
Colitis, Ulcerative 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ENTYVIO
Intervention Trials
Crohn Disease 18
Colitis, Ulcerative 18
Colitis 16
Ulcer 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ENTYVIO

Trials by Country

Trials by Country for ENTYVIO
Location Trials
United States 180
Canada 15
Ukraine 11
Italy 9
Netherlands 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ENTYVIO
Location Trials
Texas 10
Illinois 9
Tennessee 8
North Carolina 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ENTYVIO

Clinical Trial Phase

Clinical Trial Phase for ENTYVIO
Clinical Trial Phase Trials
Phase 4 12
Phase 3 4
Phase 2 9
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ENTYVIO
Clinical Trial Phase Trials
Not yet recruiting 13
Recruiting 11
Completed 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ENTYVIO

Sponsor Name

Sponsor Name for ENTYVIO
Sponsor Trials
Takeda 20
Millennium Pharmaceuticals, Inc. 8
Geert D'Haens 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ENTYVIO
Sponsor Trials
Industry 30
Other 15
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Express Scripts
Mallinckrodt
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.